LGVN Stock Forecast: Longeveron, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.66

The median 12-month analyst price target for Longeveron, Inc. is $80. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$5.6M
Ticker Nerd rank
44/ 100
Median analyst target
$80
Analysts covering
1
Revenue$287K−9.2% y/y
Operating income−$6.2M
Net income−$6.1M
Free cash flow−$5.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Longeveron, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
44/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Revisions
68
Growth
53
Issuance
48
Quality
36
Volatility
20
Value
9
Momentum
7

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LGVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LGVN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$80
Low
$80
Median
$80
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026Maxim GroupDowngradeHold—
4 May 2026HC Wainwright & Co.MaintainsBuy$10 → $8.00
15 Aug 2025Roth CapitalMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024Roth MKMInitiatesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Sept 2024HC Wainwright & Co.ReiteratesBuy—
27 Aug 2024Maxim GroupMaintainsBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
31 July 2024HC Wainwright & Co.ReiteratesBuy—
29 July 2024HC Wainwright & Co.MaintainsBuy—
17 May 2024HC Wainwright & Co.ReiteratesBuy—
29 Apr 2024HC Wainwright & Co.MaintainsBuy—
4 Dec 2023HC Wainwright & Co.InitiatesBuy—
1 June 2023EF HuttonAssumesBuy$13
16 May 2023EF HuttonReiteratesBuy—
9 May 2023EF HuttonReiteratesBuy—
27 Mar 2023EF HuttonReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LGVN.

Market Radar

This page is one stock. Monday covers all of them.

LGVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

LGVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
4.7×

Cheaper than 22% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−9.2%

Higher than 17% of US stocks

Earnings growth (YoY)
—
Gross margin
63.4%

Higher than 76% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−203.6%

Higher than 7% of US stocks

Return on assets
−90.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Longeveron, Inc. has a market value of $5.6M.

  • Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter shrank 9.2% year on year.

  • Net income over the same four quarters: −$23.5M, a −1977.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.7M.

  • Shares outstanding: 31.7M.

  • Longeveron, Inc. employs 38 people — $31K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

LGVN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LGVNLongeveron, Inc.$5.6M44
TOVXTheriva Biologics, Inc.$5.5M30
EVGNEvogene Ltd.$5.7M38
XCURExicure, Inc.$5.7M61
TPSTTempest Therapeutics, Inc.$5.7M53
OPHICollPlant Biotechnologies Ltd.$5.9M28
VIVSVivoSim Labs, Inc.$5.3M25

Take a look at LGVN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Longeveron, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LGVN

What is the LGVN stock price forecast for 2026-2027?

The median 12-month analyst price target for Longeveron, Inc. is $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LGVN stock a buy right now?

Of the 1 analyst covering Longeveron, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Longeveron, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LGVN?

As at 21 Nov 2026, Longeveron, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will LGVN stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $80, and Ticker Nerd's factor model ranks Longeveron, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LGVN stock forecast for 2030?

No analyst covering Longeveron, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $80 over the next 12 months.

What does Longeveron, Inc. do?

Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions.

Company

About Longeveron, Inc.

Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.

CEO Mr. Stephen H. Willard Esq. · 38 employees · United States · https://longeveron.com